Funding for this research was provided by:
Received: 31 January 2020
Accepted: 11 June 2020
First Online: 1 July 2020
Ethics approval and consent to participate
: Specific ethical and regulatory approval from independent ethics committees or health authorities was not required for this non-interventional, anonymous survey. The survey participants provided their prior general consent to exploitation of the anonymised data.
: Not applicable.
: Pascal Demoly was a consultant and a speaker for ALK, Stallergenes Greer, IQVIA, Chiesi, AstraZeneca, ThermoFisher Scientific, Ménarini, Bausch & Lomb, Mylan, ASIT Biotech, Novartis, Sanofi, and Regeneron in 2010–2019. Carmen Vidal has received consulting fees, honoraria for lectures and/or research funding from Stallergenes Greer, ALK-Abello and Leti. Andrea Matucci has been a consultant and speaker for Merck Sharp and Dohme, AstraZeneca and Novartis. Oliviero Rossi has been a speaker for GlaxoSmithKline, Stallergenes, Alk-Abello Chiesi and Medapharm.